Ocular Therapeutix, INC Form 4 insider transactions

Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, Inc., transferred 50,092 shares of common stock to his spouse on June 16, 2026.

Ocular Therapeutix director Charles M. Warden was granted 14,000 restricted stock units and 44,000 stock options on June 10, 2026.

Director Adrienne L. Graves was granted 14,000 restricted stock units and 44,000 stock options by Ocular Therapeutix, Inc.

CFO Jason Shand Robins received a grant of 15,441 restricted stock units and 14,024 stock options from Ocular Therapeutix.

Director Seung Suh Hong was granted 14,000 restricted stock units and 44,000 stock options by Ocular Therapeutix, Inc.

Director Richard L. Lindstrom, M.D. was granted 14,000 restricted stock units and 44,000 stock options by Ocular Therapeutix, Inc.

Ocular Therapeutix director Merilee Raines was granted 14,000 restricted stock units and 44,000 stock options.

Ocular Therapeutix director Leslie J. Williams was granted 14,000 restricted stock units and 44,000 stock options.

Chief Medical Officer Nadia Waheed sold 14,828 shares of Ocular Therapeutix to cover tax liabilities following the vesting of restricted stock units.

CEO Pravin Dugel reports a sell-to-cover tax transaction and a transfer of shares to an irrevocable trust.

Chief Scientific Officer Jeffrey S. Heier sold 3,018 shares of Ocular Therapeutix common stock to satisfy tax obligations.

Chief Strategy Officer Sanjay Nayak sold 1,858 shares of Ocular Therapeutix to satisfy tax withholding obligations.

Pravin Dugel, Director and Officer of Ocular Therapeutix, Inc., transferred 394,696 shares to his spouse on April 9, 2026.

Ocular Therapeutix's Executive Chairman, President, and CEO, Pravin Dugel, sold 20,056 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Ocular Therapeutix's Chief Development Officer, Peter Kaiser, sold 2,810 shares of common stock at a weighted average price of $8.28 to cover tax withholding obligations related to restricted stock unit vesting.

Ocular Therapeutix's Chief Scientific Officer, Jeffrey S. Heier, executed a pre-planned sale of 3,057 common shares to cover tax withholding obligations related to RSU vesting.

Ocular Therapeutix's Chief Strategy Officer, Sanjay Nayak, sold 1,759 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Ocular Therapeutix's Chief Medical Officer, Nadia Waheed, sold 3,510 shares of common stock at a weighted average price of $7.74 to cover tax withholding obligations.

Ocular Therapeutix Director Richard L. Lindstrom, M.D. purchased 60,229 shares of common stock at a weighted average price of $7.66.

Ocular Therapeutix's Chief Operating Officer, Donald Notman, sold shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Ocular Therapeutix, Inc. reported equity grants to its Global Chief Commercial Officer, David Wayne Robinson, including 136,000 restricted stock units and options for 416,000 shares.

Ocular Therapeutix's Interim CFO, Jason Shand Robins, was granted 33,000 stock options with an exercise price of $11.45.

Ocular Therapeutix's Chief Commercial Officer, Steve Lawrence Meyers, received significant equity grants, including restricted stock units and stock options, on January 2, 2026.

Ocular Therapeutix's Chief Legal Officer, Todd Anderman, was granted 64,900 restricted stock units and 197,650 stock options.

Ocular Therapeutix's Chief Strategy Officer, Sanjay Nayak, was granted 64,900 restricted stock units and options for 197,650 shares on January 2, 2026.

Ocular Therapeutix's Chief Development Officer, Peter Kaiser, was granted 79,112 restricted stock units and 240,932 stock options, aligning his incentives with long-term company performance.

Ocular Therapeutix's Chief Business Officer, Namrata Saroj, received substantial equity grants, including restricted stock units and stock options, aligning incentives with long-term company performance.

Ocular Therapeutix's Chief Medical Officer, Nadia Waheed, received significant equity grants, including restricted stock units and stock options, effective January 2, 2026.

Ocular Therapeutix's Chief Scientific Officer, Jeffrey S. Heier, received grants of restricted stock units and stock options, alongside an employee stock purchase plan acquisition.

Ocular Therapeutix's Chief Financial and Operating Officer, Donald Notman, received significant equity grants, including restricted stock units and stock options, aligning his interests with long-term company performance.